Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

May 31, 2024

Primary Completion Date

April 11, 2028

Study Completion Date

April 11, 2028

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Telisotuzumab Vedotin

Intravenous (IV) Infusion

DRUG

Osimertinib

Oral: Tablet

DRUG

Cisplatin

IV Infusion

DRUG

Carboplatin

IV Infusion

DRUG

Pemetrexed

IV Infusion